Nuveen’s Eledon Pharmaceuticals ELDN Stock Holding History

Nuveen’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$235K	Hold	76,292	–	–	﹤0.01%	3066
2025 Q4	$115K	Hold	76,292	–	–	﹤0.01%	3204
2025 Q3	$198K	Hold	76,292	–	–	﹤0.01%	3153
2025 Q2	$207K	Buy	+76,292	New	+$229K	﹤0.01%	3150

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Nuveen's ELDN Position: Q1 2026 in Review

Nuveen held its Eledon Pharmaceuticals (ELDN) position steady in Q1 2026 at 76,292 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Nuveen first reported a position in ELDN in Q2 2025 and has held it in 4 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

Nuveen held 76,292 shares of Eledon Pharmaceuticals worth $235K as of Q1 2026.
Nuveen left its Eledon Pharmaceuticals share count unchanged in Q1 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3066 holding.
Nuveen first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.